12 completed, 3 unknown, 3 withdrawn, 2 active not recruiting. 10 Phase 2, 6 Phase 1, 5 Not applicable, 2 Early Phase 1, 2 Phase 3.
Follow Squamous Cell Carcinoma of the Oral Cavity: new trials by email Literature Review of Squamous Cell Carcinoma of the Oral Cavity trials Research Report on Squamous Cell Carcinoma of the Oral Cavity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antitumor-B KAC PK Study Antitumor B KAC - Squamous Cell Carcinoma of the Oral Cavity | Phase 1 | Withdrawn | Medical College of Wisconsin | 2026-12-01 | 2025-03-18 | |
| Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC Cisplatin, Radiation therapy, Vorinostat - HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2025-06-01 | 2025-04-04 | |
| Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome data collection - Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx | Recruiting | AIO-Studien-gGmbH | 120 | 2024-11-07 | 2024-11-13 | |
| CHG0521 Oral Coating in Patients with Solid Tissue Tumor/Recurrent/Metastatic TSCC CHG0521 Oral Coating - Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity | Not applicable | Unknown | Guangzhou University of Traditional Chinese Medicine | 30 | 2024-10-15 | 2024-09-23 |
| De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Eliminating RT to the elective neck, RT standard of care - Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx | Phase 2 / Phase 3 | Recruiting | University of Erlangen-Nürnberg Medical School | 508 | 2024-01-26 | 2026-03-13 |
| Contribution of Residual Tumour DNA Testing on the Surgical Bed Circulating tumor DNA detection - Squamous Cell Carcinoma of the Oral Cavity | Not applicable | Active not recruiting | Centre Henri Becquerel | 31 | 2024-01-08 | 2026-01-02 |
| Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer Hypofractionated Postoperative Radiotherapy - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Active not recruiting | American College of Radiology | 14 | 2023-11-08 | 2025-07-24 |
| Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer cRGD-ZW800-1. - Squamous Cell Carcinoma of the Head and Neck, Oral Cancer | Phase 2 | Completed | Erasmus Medical Center | 31 | 2022-07-12 | 2026-09-14 |
| Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) Cemiplimab-Rwlc - Head and Neck Squamous Cell Carcinoma, HNSCC | Phase 2 | Withdrawn | University of Miami | 2022-07-01 | 2022-08-04 | |
| Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer Antitumor B - Squamous Cell Carcinoma of the Oral Cavity | Early Phase 1 | Completed | Medical College of Wisconsin | 6 | 2021-08-24 | 2025-01-16 |
| CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer Nivolumab, Surgery, Radiotherapy, Nivolumab, Surgery, Chemoradiotherapy - Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Completed | The Clatterbridge Cancer Centre NHS Foundation Trust | 21 | 2019-05-10 | 2025-02-25 |
| Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study Sitravatinib, Nivolumab - Squamous Cell Carcinoma, Head And Neck, Squamous Cell Carcinoma Mouth | Early Phase 1 | Completed | University Health Network, Toronto | 10 | 2018-08-30 | 2023-07-27 |
| Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Nivolumab, Cetuximab - Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 95 | 2017-12-20 | 2026-04-02 |
| Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma surgical excision - Squamous Cell Carcinoma of the Oral Cavity | Not applicable | Unknown | Cairo University | 10 | 2017-12-01 | 2017-12-06 |
| Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity GL-0817, Hiltonol, Sargramostim - Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Completed | Gliknik Inc. | 80 | 2017-03-30 | 2022-03-08 |
| Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients β-glucan - Squamous Cell Carcinoma of the Oral Cavity | Not applicable | Unknown | National Taiwan University Hospital | 130 | 2017-03-22 | 2020-05-14 |
| IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity IRX-2, Cyclophosphamide, Indomethacin - Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Completed | Brooklyn ImmunoTherapeutics, LLC | 105 | 2016-01-11 | 2024-01-30 |
| Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity IPH2201, Standard Surgery, Postsurgical Adjuvant Therapy - Squamous Cell Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Terminated | Innate Pharma | 3 | 2014-12-01 | 2017-01-04 |
| A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck GC4419 - Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx | Phase 1 | Completed | Galera Therapeutics, Inc. | 30 | 2013-08-01 | 2016-09-22 |
| Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity contralateral healthy tissue biopsy - Squamous Cell Carcinoma of the Oral Cavity, Leukoplakia Oral | Not applicable | Completed | Institut Pasteur | 100 | 2012-06-15 | 2022-04-26 |
Showing 20 of 24. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (24) · Carcinoma, Squamous Cell (5) · Head and Neck Neoplasms (3) · Neoplasms (2) · Laryngeal Diseases (1) · Leukokeratosis, Hereditary Mucosal (1) · Mouth Neoplasms (1) · Neoplasms, Squamous Cell (1) · Oropharyngeal Neoplasms (1) · Recurrence (1) · Stomatitis (1)
Carcinoma (24) · Neoplasms by Histologic Type (24) · Neoplasms by Site (24) · Neoplasms, Glandular and Epithelial (24) · Neoplasms (22) · Head and Neck Neoplasms (21) · Carcinoma, Squamous Cell (19) · Neoplasms, Squamous Cell (5) · Stomatognathic Diseases (3) · Mouth Diseases (2) · Otorhinolaryngologic Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1) · Genetic Diseases, Inborn (1) · Otorhinolaryngologic Neoplasms (1)
Cisplatin (3) · Cyclophosphamide (3) · Nivolumab (3) · Radiotherapy (3) · Geritol (2) · Indomethacin (2) · Surgical Procedures, Operative (2) · Zinc (2) · Anti-Inflammatory Agents, Non-Steroidal (1) · Antitumor B (1) · Cetuximab (1) · Chemoradiotherapy (1) · Chemoradiotherapy, Adjuvant (1) · Data Collection (1) · Docetaxel (1)
Medical College of Wisconsin (2) · AIO-Studien-gGmbH (1) · American College of Radiology (1) · Brooklyn ImmunoTherapeutics, LLC (1) · CEL-SCI Corporation (1) · Cairo University (1) · Case Comprehensive Cancer Center (1) · Centre Henri Becquerel (1) · Erasmus Medical Center (1) · Galera Therapeutics, Inc. (1) · Gliknik Inc. (1) · Guangzhou University of Traditional Chinese Medicine (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Icahn School of Medicine at Mount Sinai (1) · Innate Pharma (1)
United States (10) · Germany (4) · Canada (3) · France (3) · Spain (3) · United Kingdom (3) · Hungary (2) · Poland (2) · Russia (2) · Serbia (2) · Taiwan (2) · Ukraine (2) · Austria (1) · Belarus (1) · Belgium (1)
Aftab Mahmood, MD (1) · Andrew Sikora, MD, PhD (1) · Antoine Gessain, PhD (1) · Charles Kunos, MD, PhD (1) · Christine H. Chung, M.D. (1) · Christopher M Lee, MD (1) · Chukwuemeka Ikpeazu, MD (1) · Douglas Adkins, MD (1) · Etta Pisano, MD (1) · Eyal Talor, PhD (1) · Gregory T Wolf, MD, FACS (1) · John Buatti, MD (1) · Jon T. Holmlund, MD (1) · Joseph Sacco, MBChB (1)
PMID 12719478, PMID 15905548, PMID 19197294, PMID 22437938, PMID 23083061, PMID 26186556, PMID 27183652, PMID 27696591, PMID 28498880, PMID 32738599, PMID 34599023, PMID 35676062, PMID 40191245, PMID 40905435, PMID 42537452
2009 (1), 2014 (1), 2016 (1), 2017 (1), 2019 (1), R01CA205633 (1)